Lunai Bioworks已成功完成一笔价值2000万美元的优先股发行。此次融资的核心目的在于收购中枢神经递送及神经治疗领域的相关知识产权组合。这一战略性举措标志着该公司在强化其神经科学平台方面迈出了关键一步。
Lunai Bioworks已成功完成一笔价值2000万美元的优先股发行。此次融资的核心目的在于收购中枢神经递送及神经治疗领域的相关知识产权组合。这一战略性举措标志着该公司在强化其神经科学平台方面迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.